文献速递胸部肿瘤乳腺癌消化系统肿瘤

实体瘤老年患者的两步衰弱评估策略:决策曲线分析

A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis.
PubMed 文献 · J Clin Oncol · 2022-10-28

该研究基于ELCAPA队列(2007年2月至2019年12月)纳入1648例年龄≥70岁的前列腺、乳腺、结直肠或肺癌门诊患者,中位年龄81岁,其中1428例(87%)为衰弱。G8和改良G8筛查识别衰弱患者的敏感度分别为85%和86%,特异度分别为59%和60%。决策曲线分析显示,在预设阈值概率下,衰弱筛查相比全部患者接受老年综合评估(GA)策略未显示临床获益,且无筛查工具能减少非衰弱患者的不必要GA。

要点

  • G8识别衰弱患者敏感度85%(95%CI 84-87)、特异度59%(95%CI 57-61),改良G8敏感度86%(95%CI 84-87)、特异度60%(95%CI 58-63)。
  • 在阈值概率0.25时,识别衰弱患者的净获益:G8为0.72、改良G8为0.72、GA为0.82。
  • 在阈值概率0.33时,净获益分别为G8 0.71、改良G8 0.72、GA 0.80;在0.5时分别为0.68、0.69、0.73。

核心结论

  • 尽管衰弱筛查试验显示良好的诊断准确性,但筛查相比全部患者接受GA策略未显示临床获益。
  • 除诊断准确性外,净获益方法对于评估试验的临床价值是必要的。

研究设计与样本

  • 对ELCAPA队列研究(ClinicalTrials.gov标识符NCT02884375)中2007年2月至2019年12月纳入的年龄≥70岁的前列腺、乳腺、结直肠或肺癌门诊患者进行横断面分析。
  • 基于GA结果确定G8老年筛查工具(G8)和改良G8评分识别衰弱患者的诊断准确性。
  • 使用决策曲线分析计算衰弱筛查在不同阈值概率下检测衰弱患者和避免非衰弱患者不必要GA的获益。

主要发现

  • 共纳入1648例患者(中位年龄81岁),其中1428例(87%)为衰弱。
  • G8的敏感度和特异度分别为85%(95%CI 84-87)和59%(95%CI 57-61);改良G8评分分别为86%(95%CI 84-87)和60%(95%CI 58-63)。
  • 在阈值概率0.25时,识别衰弱患者的净获益为G8 0.72、改良G8 0.72、GA 0.82。
  • 在阈值概率0.33时,净获益分别为G8 0.71、改良G8 0.72、GA 0.80。
  • 在阈值概率0.5时,净获益分别为G8 0.68、改良G8 0.69、GA 0.73。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The intended clinical value of frailty screening is to identify unfit patients needing geriatric assessment (GA) and to prevent unnecessary GA in fit patients. These hypotheses rely on the sensitivity and specificity of screening tests, but they have not been verified. METHODS: We performed a cross-sectional analysis of outpatients age ≥ 70 years with prostate, breast, colorectal, or lung cancer included in the ELCAPA cohort study (ClinicalTrials.gov identifier: NCT02884375) between February 2007 and December 2019. The diagnostic accuracy of the G8 Geriatric Screening Tool (G8) and modified G8 scores for identifying unfit patients was determined on the basis of GA results. We used decision curve analysis to calculate the benefit of frailty screening for detecting unfit patients and avoiding unnecessary GA in fit patients across different threshold probabilities. RESULTS: We included 1,648 patients (median age, 81 years), and 1,428 (87%) were unfit. The sensitivity and specificity were, respectively, 85% (95% CI, 84 to 87) and 59% (95% CI, 57 to 61) for G8, and 86% (95% CI, 84 to 87) and 60% (95% CI, 58 to 63) for the modified G8 score. For decision curve analysis, the net benefit (NB) for identifying unfit patients were 0.72 for G8, 0.72 for the modified G8, and 0.82 for GA at a threshold probability of 0.25. At a threshold probability of 0.33, the NBs were 0.71, 0.72, and 0.80, respectively. At a threshold probability of 0.5, the NBs were 0.68, 0.69, and 0.73, respectively. No screening tool reduced unnecessary GA in fit patients at predefined threshold probabilities. CONCLUSION: Although frailty screening tests showed good diagnostic accuracy, screening showed no clinical benefits over the GA-for-all strategy. NB approaches, in addition to diagnostic accuracy, are necessary to assess the clinical value of tests.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. González Serrano A, Laurent M, Barnay T, et al. A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis. J Clin Oncol. 2022. PMID: 36306481. doi:10.1200/JCO.22.01118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。